Collaborations and partnerships are an essential part of NOXXON's business strategy and we are open to discussing partnering opportunities either relating to our proprietary programs in clinical development or our Spiegelmer* technology.
We are actively collaborating with international pharmaceutical leaders, academic investigators worldwide and other research organizations to advance NOXXON’s portfolio.
The list below contains some of NOXXON's scientific advisors and collaborators.
|
University Hospital Bonn
Prof. Dr. Frank A. Giordano
NOXXON collaborates with Prof. Dr. Frank A. Giordano at University Hospital Bonn (UKB), Germany, on the ongoing GLORIA study in newly diagnosed glioblastoma (GBM) patients. Dr. Giordano is Director and Chair of the Department of Radiation Oncology at the UKB. He is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors. Dr. Giordano is lead investigator of the study that in addition to the UKB is being conducted at clinical centers in Mannheim, Essen, Leipzig, Münster and Tübingen, Germany. More information about the GLORIA study can be found at ClinicalTrials.gov number NCT04121455.
Prof. Dr. Michael Hölzel
Prof. Dr. Michael Hölzel is Director at the Institute for Experimental Oncology at University Hospital Bonn (UKB), Germany, where the research is driven by exploration of the complexity and dynamics of cellular and non-cellular interactions within the tumor microenvironment. He has long-standing research expertise in the field of tumor biology and functional genomics with a particular focus on neural crest derived tumors. Prof. Hölzel leads a research project to characterize the NOX-A12-mediated modulation of tumor microenvironment in glioblastoma patients by multiparameter immunofluorescence microscopy.
|
|
Merck & Co. / MSD
NOXXON and Merck & Co., Inc./MSD announced their second clinical collaboration on July 21, 2021 in the upcoming Phase 2 clinical trial to evaluate safety and efficacy of NOXXON’s anti-CXCL12 agent, NOX-A12, in combination with MSD’s anti-PD-1, Keytruda® (pembrolizumab) and two different chemotherapy regimens as second-line therapy in patients with microsatellite stable pancreatic cancer.
Metastatic solid tumors that do not respond to checkpoint inhibitors:
NOXXON and Merck & Co., Inc./MSD announced a collaboration on Dec 15, 2016 under which the two companies will collaborate in a phase 1/2 clinical trial of NOXXON’s anti-CXCL12 agent, NOX-A12, and MSD’s anti-PD-1 inhibitor, Keytruda® (pembrolizumab), in a two-part, open-label phase 1/2 study is to evaluate pharmacodynamic effects and safety of NOX-A12 as a monotherapy in addition to safety and efficacy of NOX-A12 in combination with Keytruda® in patients with metastatic colorectal and pancreatic cancer.
The clinical trial and thus the collaboration were completed in H1 2021.
|
National Center for Tumor Diseases (NCT)
NOXXON collaborated with Prof. Dr. Dirk Jäger, and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, Germany, one of the leading centers for cancer research and treatment, to conduct their completed clinical trial in metastatic colorectal and pancreatic cancer.
|
At NOXXON we believe in the value of collaboration. We are seeking partners who share our vision to create impactful therapies and bring our innovative technology to market. For more information on partnering or collaborating with NOXXON please contact:
Business Development at This email address is being protected from spambots. You need JavaScript enabled to view it.
